Figure 6 from Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo

NaJa cells are well suited to study tumor–immune system interactions and their modulation by encorafenib. A, Bulk RNA-seq of NaJa cells treated with 0.5 μmol/L encorafenib for either 1 day or 5 days, showing an upregulation of markers for antigen processing and presentation and (B) HLA/MHC expression. Shown are the log2 FCs of cells treated with encorafenib versus DMSO control. C, Cytokine array of NaJa cell supernatant after a 5-day treatment with either 0.5 μmol/L encorafenib, 1 μmol/L afatinib, or a combination of both (E + A). Shown are the log2 FCs to a DMSO control. Array membranes and cell line–specific heatmaps are displayed in Supplementary Fig. S15. Discussed cytokines are highlighted in yellow. D, Additional heatmap of bulk RNA-seq of encorafenib-treated NaJa cells, showing upregulation or downregulation of transcripts of the GOBP-negative regulation of immune effector process. The genes that are represented have an adjusted P value of